Sociodemographic Factors Influencing Access to Chimeric Antigen T-Cell Receptor Therapy for Patients With Non-Hodgkin Lymphoma
Clinical Lymphoma Myeloma and Leukemia · 2025
DOI: 10.1016/j.clml.2024.09.010 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical Lymphoma Myeloma and Leukemia, 2025. Verfasst von Somya Khare und 12 weiteren Autor:innen. Beteiligte Einrichtung: Center for Hematological Malignancies, Knight Cancer Institute, Oregon Health & Science University, Portland, OR. Hauptthemen laut MEDLINE: Health Services Accessibility, Lymphoma, Non-Hodgkin, Immunotherapy, Adoptive, Receptors, Chimeric Antigen. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 13 Literaturangaben.
Abstract (Originalsprache)
BACKGROUND: Chimeric antigen receptor T-cell (CAR-T) therapies are available for patients with Non-Hodgkin Lymphoma (NHL); however, their use has been limited in accessibility due to nondisease factors. PATIENTS & METHODS: We conducted a retrospective study evaluating the influence of sociodemographic factors on access and outcomes after CAR-T therapy for adult patients with B-cell NHL in our institution treated between 2016 and 2023. RESULTS: Among 154 patients treated with CAR-T, 43% were older than 65 years, 68% male, and 14% non-White (including Hispanic). Of those under 65, 66% had private insurance, while 82% over 65 had Medicare. Most patients (85%) were from in-state, 29% from areas below the national poverty level and 18% from nonmetropolitan areas. Distance to the treatment center was greater than 30, 60 or 120 miles for 52%, 40% and 29% of patients, respectively. No significant differences were found in the use of commercial versus investigational products among racial/ethnic minorities or those living >60 miles from the center. However, patients from nonmetropolitan areas and those below the national poverty level were less likely to receive commercial products. With a median follow-up of 11 months, the 1-year overall survival (OS) was 63.2% (95th CI 59.9%-66.8%). Poverty was associated with lower 1-year OS (HR 0.4, 95th CI 0.17-0.90, P = .031). CONCLUSION: Our study shows that CAR-T therapy can be delivered across sociodemographic barriers and underscores the importance of considering social determinants of health to optimize access for all patients.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Center for Hematological Malignancies, Knight Cancer Institute, Oregon Health & Science University, Portland, OR.
- Center for Hematological Malignancies, Knight Cancer Institute, Oregon Health & Science University, Portland, OR. Electronic address: nemeceke@ohsu.edu.
Zitieren
APA
Khare, S., Williamson, S., O'Barr, B., Schachter, L., Chen, A., Hayes-Lattin, B., Leonard, J., Desai, A., Ferreira-Gandolfo, P., Christmas, K., Lackey, D., Maziarz, R. T., & Nemecek, E. R. (2025). Sociodemographic Factors Influencing Access to Chimeric Antigen T-Cell Receptor Therapy for Patients With Non-Hodgkin Lymphoma. Clinical Lymphoma Myeloma and Leukemia. https://doi.org/10.1016/j.clml.2024.09.010
Vancouver
Khare S, Williamson S, O'Barr B, Schachter L, Chen A, Hayes-Lattin B, et al. Sociodemographic Factors Influencing Access to Chimeric Antigen T-Cell Receptor Therapy for Patients With Non-Hodgkin Lymphoma. Clinical Lymphoma Myeloma and Leukemia. 2025. doi:10.1016/j.clml.2024.09.010
BibTeX
@article{Khare2025,
author = {Khare, Somya and Williamson, Staci and O'Barr, Brittany and Schachter, Levanto and Chen, Andy and Hayes-Lattin, Brandon and Leonard, Jessica and Desai, Amrita and Ferreira-Gandolfo, Peter and Christmas, Kevin and Lackey, Denise and Maziarz, Richard T and Nemecek, Eneida R},
title = {Sociodemographic Factors Influencing Access to Chimeric Antigen T-Cell Receptor Therapy for Patients With Non-Hodgkin Lymphoma},
journal = {Clinical Lymphoma Myeloma and Leukemia},
year = {2025},
doi = {10.1016/j.clml.2024.09.010}
}
EUVIMED